NovoCure shareholders narrowly approve equity plan by 50.3% margin at annual meeting

Filed June 5, 2026 · Period ending June 3, 2026 · ~1 min read

Key Changes

• medium

  Amended 2024 equity incentive plan passed with just 50.3% approval (41.7M for vs 41.2M against), revealing significant shareholder division over executive compensation structure

  Item 5.07 verify on EDGAR →
• low

  Say-on-pay vote approved but drew 9% opposition (7.4M against), higher than typical for routine advisory votes on executive compensation

  Item 5.07 verify on EDGAR →
• low

  All 11 director nominees elected to one-year terms through 2027 annual meeting with votes ranging from 79.5M to 82.5M shares in favor

  Item 5.02 verify on EDGAR →